Description
SC-201 (resminostat) is a histone deacetylase inhibitor that has been evaluated in advanced colorectal carcinoma. This epigenetic modifier works by altering gene expression patterns in cancer cells. It belongs to the class of HDAC inhibitors that target chromatin remodeling mechanisms in solid tumors.
Mechanism of Action
Resminostat selectively inhibits histone deacetylases, particularly HDAC1, HDAC3, and HDAC6, leading to increased acetylation of histone and non-histone proteins. This epigenetic modification results in altered gene expression, promoting cancer cell cycle arrest, differentiation, and apoptosis while potentially enhancing immune recognition of tumor cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.